MORE ON RESEARCH IN MOTION (RIMM)
September 16, 2011
Research in Motion (RIMM) has moved up from its morning lows. Our Smart MoneyIndicator shows that smart money is selling Research In Motion into the strength.
Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
Research in Motion (RIMM) has moved up from its morning lows. Our Smart MoneyIndicator shows that smart money is selling Research In Motion into the strength.
Readers may want to start from my previous article on Research In Motion titled What Is The True Value Of Research In Motion? In the article I described various scenarios for Research In Motion (RIMM). One of the scenarios I described was for Research in Motion to continue on its present path. The earnings report just issued shows that prediction is coming true. The earnings for the quarter were $0.80 compared to the consensus of $0.88. Revenues for the quarter fell 10% to $4.17 billion compared to the consensus of $4.47 billion. For the next quarter, the company projects revenues
It is time to take profits on Acorda Therapeutics (ACOR). Consider taking profits on the entire position of Acorda Therapeutics right here at $23.08. Ampyra, the drug that has caused most excitement in Acora Therapeutics, is not proving to be a very good drug as we had predicted. Please see prior post on Acorda Therapeutics. However, this is company is highly promotional and periodically tends to release meaningless press releases that run the stock up. The plan is to short Acorda Therapeutics again on any run up. A signal will be provided in real-time on the
Vivus (VVUS ) shares have moved up strongly on the news that FDA has agreed to an early re-submission of the QNEXA NDA for the treatment of obesity. The road is not all clear for Vivus. There are still major issues that need to be resolved by Vivus including birth defect concerns, cardiovascular concerns, and epilepsy concerns. If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.
We are taking partial profits on a 5% tranche of Pan American Silver (PAAS) at $31.82.
We are taking profits and exiting the Deutsche Bank (DB) position right here at $36.20. We had not intended to exit Deutsche Bank position so quickly, but since we were fortunate to garner a large profit in a very short time, in this market environment it is prudent to book profits.
A careful analysis of the earnings report of Best Buy (BBY) shows that the business Best Buy may be losing to online competitors is less than some reports by analysts. An encouraging statistic in the Best Buy report is that 40% of leases expire in the next 5 years. This provides Best Buy with the opportunity to close stores and focus more on its online business.
Best Buy (BBY) reported earnings this morning. Both earnings and projections for Best Buy were only slightly below consensus. Best Buy’s stock has taken a major hit primarily because of negative commentary by the analysts. ‘Best Buy has become a show room for Amazon (AMZN),’ has become the most often repeated phrase. Anyone contemplating short selling this stock should think twice because the short interest stands at 12.5% of Best Buy float. Potential for a short squeeze is high. If and when six screens of the ZYX Change Method are satisfied, we will issue a